Pds Biotechnology CORP 8-K filings

PDS Biotechnology Corporation announced that an abstract featuring updated data from the VERSATILE-002 trial of Versamune HPV in combination with KEYTRUDA for head and neck cancer has been accepted for presentation at the ESMO Congress 2024.

PDS Biotechnology has received FDA agreement on the design of its Phase 3 clinical trial for Versamune HPV in HPV16-positive head and neck cancer, with the trial expected to begin in Q4 2024.

PDS Biotechnology's stockholders approved an increase in authorized common stock and elected two Class C directors at their 2024 annual meeting.

PDS Biotechnology reported a median overall survival of 30 months in its VERSATILE-002 Phase 2 clinical trial for head and neck cancer, with many patients approaching three years of follow-up.

PDS Biotechnology reported positive updated data from its Phase 2 VERSATILE-002 clinical trial and its first quarter 2024 financial results, highlighting progress in its cancer immunotherapy programs.

PDS Biotechnology's VERSATILE-002 Phase 2 trial demonstrated a 30-month median overall survival in first-line recurrent/metastatic HPV16-positive head and neck cancer, significantly exceeding historical benchmarks.

PDS Biotechnology is progressing its cancer immunotherapy programs, showcasing encouraging survival data and plans for pivotal trials in head and neck cancer.

PDS Biotechnology Corporation has appointed Stephan Toutain as its new Chief Operating Officer, effective May 1, 2024, and granted him a stock option as an inducement.

PDS Biotechnology is shifting its clinical focus to a triple combination therapy for advanced head and neck cancer after observing strong survival and response rates in a Phase 2 trial.

PDS Biotechnology announced the publication of preclinical research and the grant of a U.S. patent, strengthening its Infectimune infectious disease vaccine platform.

PDS Biotechnology Corporation announced the retirement of its Chief Medical Officer, Lauren V. Wood, M.D., and the appointment of Kirk V. Shepard, M.D., as her successor, along with an amendment to its stock option plan.